VanEck: Bitcoin miners face a $50 billion funding gap in transitioning to AI
According to ChainCatcher, citing a report from CoinDesk, VanEck has published a report stating that Bitcoin mining companies face a short-term funding gap of approximately $50 billion for transitioning to AI infrastructure, with long-term capital needs amounting to about $221 billion. Analysts noted that market focus is shifting from contract signings to execution risks. Currently, only around 25% of the leased AI and high-performance computing capacity has been delivered in the industry, and companies missing construction milestones face “structural downgrades” from investors.
With mining profitability declining, Bitcoin mining companies are turning to AI infrastructure. Core Scientific has signed multi-billion-dollar hosting agreements with CoreWeave, and companies such as TeraWulf, Hut 8, Iren, and Cipher have also announced plans for AI and high-performance computing. VanEck pointed out that the clearest current valuation metric is the available operational power infrastructure, with companies holding AI lease contracts valued at more than ten times their operational power. The report believes that HIV E, Bitdeer, Keel, and IREN have potential upside, whereas MARA, CLSK, and RIOT remain more closely tied to the Bitcoin price.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.
TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).
